What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?

Gilead Sciences, Inc. (NASDAQ:GILD) is 1 of the champion immunotherapy stocks to bargain according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and afloat twelvemonth 2025 results connected February 10, reporting a beardown twelvemonth marked by the continued maturation of Biktarvy and Descovy, on with the palmy motorboat of Yeztugo, the world’s archetypal twice-yearly HIV prevention therapy successful the country.

Gilead Sciences, Inc. (NASDAQ:GILD) besides reported that the full fiscal Q4 revenues roseate 5% to $7.9 cardinal compared to the anterior twelvemonth period, driven chiefly by the accrued income of HIV and Liver Disease products and partially offset by little income of Veklury®.

Following the release, Gilead Sciences, Inc. (NASDAQ:GILD) received standing updates from respective analysts. Needham and Scotiabank some released bullish standing updates for the institution connected February 11, with Needham raising the terms people connected the banal to $170 from $140 portion maintaining a Buy rating, and Scotiabank lifting the terms people to $177 from $140 and keeping an Outperform standing connected the shares.

The aforesaid day, BofA besides lifted the terms people connected Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy standing connected the shares and telling investors successful a post-earnings enactment that it is assured successful 2026 maturation for the institution owed to coagulated fiscal Q4 dynamics. It added that it nary longer models Yeztugo cannibalization of Descovy income successful 2026.

Gilead Sciences, Inc. (NASDAQ:GILD) is simply a biotech institution that advances medicines to forestall and dainty superior diseases specified arsenic cancer, immunodeficiency microorganism (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses connected aesculapian areas with unmet needs, and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.